Halliday W J, Maluish A, Isbister W H
Br J Cancer. 1974 Jan;29(1):31-5. doi: 10.1038/bjc.1974.4.
The leucocyte adherence inhibition (LAI) test, previously described for the detection of cell mediated immunity and serum blocking factors associated with murine tumours, has now been adapted for use with human cancer patients. Blood leucocytes from these patients, mixed in vitro with antigenic extracts of tumours of the same type, had their normal adherence to glass surfaces diminished. This inhibition was reversed (blocked) by the addition of the patients' own sera. Both LAI and blocking were tumour-type specific, but showed complete cross-reactivity within each type of tumour (melanoma, colon carcinoma, mammary carcinoma).The LAI test could be of great value in diagnosis and evaluation of treatment, since it seems to reproduce consistently the findings made by more elaborate techniques but has the advantage of being simple, rapid and inexpensive.
白细胞黏附抑制(LAI)试验,先前已被描述用于检测与鼠肿瘤相关的细胞介导免疫和血清阻断因子,现在已被改编用于人类癌症患者。这些患者的血液白细胞在体外与相同类型肿瘤的抗原提取物混合后,其对玻璃表面的正常黏附能力降低。通过添加患者自身的血清,这种抑制作用会被逆转(阻断)。LAI和阻断作用都是肿瘤类型特异性的,但在每种肿瘤类型(黑色素瘤、结肠癌、乳腺癌)内都表现出完全的交叉反应性。LAI试验在诊断和治疗评估中可能具有很大价值,因为它似乎能始终如一地重现更精细技术所得到的结果,而且具有操作简单、快速且成本低廉的优点。